Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Prostate Cancer
•
Medical Oncology
•
Endocrinology
•
Primary Care
Would you prescribe semaglutide for weight gain from androgen deprivation therapy for prostate cancer?
Related Questions
How do you manage enfortumab vedotin related DKA that is refractory to standard therapy (insulin, fluids, etc)?
In which patients are referring for focal gland therapy for localized prostate cancer?
Do you offer RT both to the prostate and synchronous oligometastases in de novo oligometastatic prostate cancer?
How do you follow/manage patients with metastatic prostate cancer with undetectable PSA and castration-sensitive but active disease on PSMA PET?
Are there any concerns with live vaccine innoculation and patients who are on denosumab?
How do you manage PSA progression while a patient is on xofigo or pluvicto?
For an older patient with hormone-sensitive high-volume, high-risk prostate cancer with metastases to bone who developed toxicity with enzalutamide, what other oral AR blocker would you offer?
What is the rationale for the recent change in the NCCN criteria for very high risk prostate cancer?
Do you add ADT to RT for a patient with intermediate-risk prostate cancer with discordant Decipher and ArteraAI results?
What are your top takeaways in GU Cancers from ESMO 2024?
